| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Throughout the last three months, 16 analysts have evaluated Veeva Systems (NYSE:VEEV), offering a diverse set of opinions from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 4 | 6 | 5 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 3 | 4 | 4 | 1 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 0 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $226.25, a high estimate of $260.00, and a low estimate of $173.00. Observing a downward trend, the current average is 6.71% lower than the prior average price target of $242.53.
A comprehensive examination of how financial experts perceive Veeva Systems is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jailendra Singh | Truist Securities | Lowers | Hold | $197.00 | $203.00 |
| Tyler Radke | Citigroup | Lowers | Buy | $256.00 | $274.00 |
| Karl Keirstead | UBS | Lowers | Neutral | $185.00 | $235.00 |
| Saket Kalia | Barclays | Lowers | Overweight | $220.00 | $245.00 |
| David Hynes | Canaccord Genuity | Lowers | Hold | $210.00 | $220.00 |
| David Grossman | Stifel | Lowers | Buy | $210.00 | $250.00 |
| Kirk Materne | Evercore ISI Group | Lowers | In-Line | $200.00 | $230.00 |
| Craig Hettenbach | Morgan Stanley | Lowers | Underweight | $173.00 | $210.00 |
| Joe Vruwink | Baird | Lowers | Outperform | $245.00 | $255.00 |
| Brad Sills | B of A Securities | Lowers | Neutral | $204.00 | $240.00 |
| Ryan MacDonald | Needham | Maintains | Buy | $260.00 | $260.00 |
| Brent Bracelin | Piper Sandler | Lowers | Overweight | $235.00 | $245.00 |
| Joe Vruwink | Baird | Raises | Outperform | $255.00 | $251.00 |
| Ryan MacDonald | Needham | Maintains | Buy | $260.00 | $260.00 |
| Rishi Jaluria | RBC Capital | Maintains | Outperform | $250.00 | - |
| Brian Peterson | Raymond James | Maintains | Outperform | $260.00 | $260.00 |
To gain a panoramic view of Veeva Systems's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Veeva Systems analyst ratings.
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry. The company's best-of-breed offerings address operating and regulatory requirements for customers ranging from small, emerging biotechnology companies to departments of global pharmaceutical manufacturers. The company leverages its domain expertise to improve the efficiency and compliance of the underserved life sciences industry, displacing large, highly customized and dated enterprise resource planning systems that have limited flexibility. Its two main products are Veeva CRM, a customer relationship management platform for companies with a salesforce, and Veeva Vault, a content management platform that tackles various functions within any life sciences company.
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Veeva Systems displayed positive results in 3 months. As of 30 April, 2024, the company achieved a solid revenue growth rate of approximately 23.56%. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Veeva Systems's net margin excels beyond industry benchmarks, reaching 24.86%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Veeva Systems's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 3.39% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Veeva Systems's ROA stands out, surpassing industry averages. With an impressive ROA of 2.67%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: Veeva Systems's debt-to-equity ratio is below the industry average. With a ratio of 0.01, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: VEEV
